MX2010005164A - Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide. - Google Patents

Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide.

Info

Publication number
MX2010005164A
MX2010005164A MX2010005164A MX2010005164A MX2010005164A MX 2010005164 A MX2010005164 A MX 2010005164A MX 2010005164 A MX2010005164 A MX 2010005164A MX 2010005164 A MX2010005164 A MX 2010005164A MX 2010005164 A MX2010005164 A MX 2010005164A
Authority
MX
Mexico
Prior art keywords
benzimidazole derivatives
novel methyl
novel
methyl
medicaments
Prior art date
Application number
MX2010005164A
Other languages
English (en)
Inventor
Sven Taylor
Hans Richter
Jean-Marc Plancher
Uwe Grether
Konrad Bleicher
Rainer E Martin
Gregory Martin Benson
Minmin Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010005164A publication Critical patent/MX2010005164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invención se refiere a nuevos derivados de bencimidazol sustituidos de la fórmula (I) (ver fórmula (I)) en la que de R1 a R10 tienen los significados definidos en la descripción y en las reivindicaciones, así como las sales y ésteres fisiológicamente aceptables de los mismos. Estos compuestos pueden utilizarse como medicamentos.
MX2010005164A 2007-11-15 2008-11-05 Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide. MX2010005164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07120737 2007-11-15
PCT/EP2008/065012 WO2009062874A2 (en) 2007-11-15 2008-11-05 Benzimidazole derivatives and their use as fxr agonists

Publications (1)

Publication Number Publication Date
MX2010005164A true MX2010005164A (es) 2010-05-27

Family

ID=40551982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005164A MX2010005164A (es) 2007-11-15 2008-11-05 Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide.

Country Status (16)

Country Link
US (2) US7825258B2 (es)
EP (1) EP2222645B1 (es)
JP (1) JP5222953B2 (es)
KR (1) KR101176721B1 (es)
CN (1) CN101855214B (es)
AR (1) AR069306A1 (es)
AU (1) AU2008323017B2 (es)
BR (1) BRPI0818813A2 (es)
CA (1) CA2704074A1 (es)
CL (1) CL2008003372A1 (es)
ES (1) ES2403592T3 (es)
IL (1) IL205207A0 (es)
MX (1) MX2010005164A (es)
PE (1) PE20090999A1 (es)
TW (1) TW200924755A (es)
WO (1) WO2009062874A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028981A1 (en) * 2008-09-11 2010-03-18 F. Hoffmann-La Roche Ag New benzimidazole derivatives
KR20110069173A (ko) * 2008-10-15 2011-06-22 에프. 호프만-라 로슈 아게 신규한 벤즈이미다졸 유도체
US8309581B2 (en) * 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA3028207A1 (en) * 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
BR112016005507B1 (pt) 2013-09-11 2023-02-07 Centre National De La Recherche Scientifique (Cnrs) Uso de um agonista do receptor farnesoide x (fxr)
WO2018153933A1 (en) 2017-02-21 2018-08-30 Genfit Combination of a ppar agonist with a fxr agonist
CN110944635A (zh) 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
TW202143958A (zh) * 2020-03-18 2021-12-01 美商梅塔克林公司 用於治療疾病之法尼醇x(farnesoid x)受體促效劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004900A1 (en) * 1998-07-20 2000-02-03 Bristol-Myers Squibb Company Substituted benzimidazole antiviral agents
CA2475633C (en) 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
US20060148805A1 (en) * 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
KR101237623B1 (ko) * 2006-06-29 2013-02-26 에프. 호프만-라 로슈 아게 벤즈이미다졸 유도체, 이의 제조방법, ｆｘｒ 작용물질로서이의 용도, 및 이를 함유하는 약학 제제
JP5204232B2 (ja) * 2007-08-27 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー Ｆｘｒアゴニストとして使用されるベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
CA2704074A1 (en) 2009-05-22
CL2008003372A1 (es) 2010-01-04
JP2011503136A (ja) 2011-01-27
JP5222953B2 (ja) 2013-06-26
WO2009062874A3 (en) 2009-07-09
CN101855214A (zh) 2010-10-06
EP2222645A2 (en) 2010-09-01
US8008503B2 (en) 2011-08-30
AU2008323017A1 (en) 2009-05-22
US7825258B2 (en) 2010-11-02
KR20100071102A (ko) 2010-06-28
KR101176721B1 (ko) 2012-08-23
ES2403592T3 (es) 2013-05-20
BRPI0818813A2 (pt) 2015-04-22
PE20090999A1 (es) 2009-07-20
WO2009062874A2 (en) 2009-05-22
AU2008323017B2 (en) 2012-12-20
TW200924755A (en) 2009-06-16
CN101855214B (zh) 2012-12-26
EP2222645B1 (en) 2013-03-20
AR069306A1 (es) 2010-01-13
US20100331371A1 (en) 2010-12-30
IL205207A0 (en) 2010-12-30
US20090131482A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
MX2010005164A (es) Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide.
TW200833324A (en) Sulfonamide derivatives
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
MX2010006565A (es) Derivados de benzimidazol sustituido por carboxilo o hidroxilo.
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
TW200738655A (en) Novel bicyclic sulfonamide derivatives
MX2010003224A (es) Derivados de biaril sulfonamida.
MX2009010218A (es) Derivados de aza-piridopirimidinona.
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
IN2012DN03337A (es)
TW200745032A (en) Novel heterobicyclic derivatives
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
MX2007004699A (es) Derivados de indol y bencimidazol.
TW200616940A (en) Novel hexafluoroisopropanol substituted ether derivatives
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
UA109037C2 (uk) Триазолопіридини
MX2009010567A (es) Derivados de imidazolidinona.
MX2010005824A (es) Derivados de aminotiazol.
MY153921A (en) Aminopyrazole derivatives
UA107784C2 (en) Inhibitor of melanin production
MX342440B (es) Derivados fluorados de aminotriazol.
MX2010001742A (es) Nuevos derivados de piperazina-amida.

Legal Events

Date Code Title Description
FG Grant or registration